Research programme: human histone methyltransferase inhibitors - Epizyme/GlaxoSmithKline

Drug Profile

Research programme: human histone methyltransferase inhibitors - Epizyme/GlaxoSmithKline

Alternative Names: DOT1L inhibitors - Epizyme; EPZ 01566; EPZ 015666; HDAC inhibitors - Epizyme; HMT inhibitors - Epizyme; HMT3 inhibitors - Epizyme; WHSC1 inhibitors - Epizyme

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Epizyme
  • Class Small molecules
  • Mechanism of Action DNA methylation inhibitors; Histone deacetylase inhibitors; Histone methyltransferase inhibitors; Protein methyltransferase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mantle-cell lymphoma
  • No development reported Cancer; Haematological malignancies; Leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Leukaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top